Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance

Burnouf, 2007, Modern plasma fractionation, Transfus Med Rev, 21, 101, 10.1016/j.tmrv.2006.11.001

Stiehm, 2008, Preparation and use of therapeutic antibodies primarily of human origin, Biologicals, 36, 363, 10.1016/j.biologicals.2008.07.002

WHO Recommendations for the production, control and regulation of human plasma for fractionation http://www.who.int/bloodproducts 2005

Lemieux, 2005, Therapeutic intravenous immunoglobulins, Mol Immunol, 42, 839, 10.1016/j.molimm.2004.07.046

Cohn, 1946, Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids, J Am Chem Soc, 68, 459, 10.1021/ja01207a034

Oncley, 1949, The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma, J Am Chem Soc, 71, 541, 10.1021/ja01170a048

Barandun, 1962, Intravenous administration of human gamma-globulin, Vox Sang, 7, 157, 10.1111/j.1423-0410.1962.tb03240.x

Sgouris, 1967, The preparation of plasmin treated immune serum globulin for intravenous use, Vox Sang, 13, 71

Barandun, 1975, Clinical tolerance and catabolism of plasmin-treated gamma-globulin for intravenous application, Vox Sang, 28, 157, 10.1111/j.1423-0410.1975.tb02755.x

Taubman, 1968, Reaction of beta-propiolactone with amino acids and its specificity for methionine, Biochem J, 106, 829, 10.1042/bj1060829

Barandun, 1982, Clinical Applications of Immunoglobulin (Gamma Globulin). A Review of Current Findings

Masuho, 1977, Development of an intravenous gamma-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human gamma-globulin, Vox Sang, 32, 175, 10.1111/j.1423-0410.1977.tb00622.x

Masuho, 1977, Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin, Vox Sang, 32, 290

McCue, 1986, Three generations of immunoglobulin G preparations for clinical use, Rev Infect Dis, 8, S374, 10.1093/clinids/8.Supplement_4.S374

Pollack, 1983, Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans, J Infect Dis, 147, 1090, 10.1093/infdis/147.6.1090

Janeway, 1968, Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons, N Engl J Med, 278, 919, 10.1056/NEJM196804252781701

Hetherington, 1984, Opsonic activity of immunoglobulin prepared for intravenous use, J Lab Clin Med, 104, 977

CHMP Guideline on requirements for plasma master file (PMF) certification http://www.emea.eu.int 2004

CHMP Guideline on the scientific data requirements for a plasma master file (PMF) http://www.emea.eu.int European Medicine Evaluation Agency 2004

Anonymous, 2005, Monograph of Human Plasma for Fractionation 01/2005:0853 Corrected

Anonymous PIC/S Site master file for plasma warehouses – PI020-3 2007

Anonymous PIC/S Site master file for source plasma establishments – PI019-3 2007

Anonymous PIC/S GMP guide for blood establishments – PE005-3 Pharmaceutical Inspection Convention 2007

Anonymous, 1995, Guide to the Preparation, Use and Quality Assurance of Blood Components

Wagstaff, 1998, GMP in blood collection and processing, Vox Sang, 74, 513, 10.1111/j.1423-0410.1998.tb05467.x

Burnouf, 2006, Current strategies to prevent transmission of prions by human plasma derivatives, Transfus Clin Biol, 13, 320, 10.1016/j.tracli.2006.11.001

Burgstaler, 2003, Apheresis: Principles and Practice, 95

Sward-Nilsson, 2006, Factors influencing factor VIII activity in frozen plasma, Vox Sang, 90, 33, 10.1111/j.1423-0410.2005.00715.x

Burnouf, 2003, Residual cell content in plasma from 3 centrifugal apheresis procedures, Transfusion, 11, 1522, 10.1046/j.1537-2995.2003.00543.x

Sonntag, 1998, Complement activation during plasma production depends on the apheresis technique, Transfus Med, 8, 205, 10.1046/j.1365-3148.1998.00150.x

Burnouf, 2004, Assessment of complement activation during membrane-based plasmapheresis procedures, J Clin Apher, 19, 142, 10.1002/jca.20019

Cardigan, 2001, The effect of leucocyte depletion on the quality of fresh-frozen plasma, Br J Haematol, 114, 233, 10.1046/j.1365-2141.2001.02907.x

CHMP Guideline on epidemiological data on blood transmissible infections for inclusion in the Guideline on the scientific data requirements for a plasma master file http://www.emea.eu.int European Medicine Agency 2005

Dicato, 1997, Intravenous Immunoglobulins in Clinical Practice, 57

Hooper, 2008, Intravenous immunoglobulins: evolution of commercial IVIG preparations, Immunol Allergy Clin North Am, 28, 765, 10.1016/j.iac.2008.06.002

Page, 1995, Fragmentation of therapeutic human immunoglobulin preparations, Vox Sang, 69, 183, 10.1111/j.1423-0410.1995.tb02592.x

Terpstra, 2006, Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product, Vox Sang, 90, 21, 10.1111/j.1423-0410.2005.00710.x

Teschner, 2007, A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process, Vox Sang, 92, 42, 10.1111/j.1423-0410.2006.00846.x

Lebing, 2003, Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography, Vox Sang, 84, 193, 10.1046/j.1423-0410.2003.00285.x

Stucki, 2008, Investigations of prion and virus safety of a new liquid IVIG product, Biologicals, 36, 239, 10.1016/j.biologicals.2008.01.004

Bertolini J Chromatographic purification of immunoglobulins downstream 2000 31 20 21

Schiff, 1994, Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action, Pediatr Allergy Immunol, 5, 63, 10.1111/j.1399-3038.1994.tb00222.x

Pierce, 2003, Risks associated with the use of intravenous immunoglobulin, Transfus Med Rev, 17, 241, 10.1016/S0887-7963(03)00038-5

Moore, 2008, Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century, Ann Allergy Asthma Immunol, 101, 114, 10.1016/S1081-1206(10)60197-4

Lane, 1983, Non-A, non-B hepatitis from intravenous immunoglobulin, Lancet, 2, 974, 10.1016/S0140-6736(83)90496-8

Yap, 1997, Intravenous Immunoglobulins in Clinical Practice, 67

Yap, 1996, Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data, Clin Ther, 18, 43, 10.1016/S0149-2918(96)80195-0

Lawlor, 1999, Transmission rates of hepatitis C virus by different batches of a contaminated anti-D immunoglobulin preparation, Vox Sang, 76, 138, 10.1046/j.1423-0410.1999.7630138.x

Kempf, 2007, Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins, Biologicals, 35, 35, 10.1016/j.biologicals.2006.01.002

Piszkiewicz, 1985, Inactivation of HTLV-III/LAV during plasma fractionation, Lancet, 2, 1188, 10.1016/S0140-6736(85)92710-2

Wells, 1986, Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma, Transfusion, 26, 210, 10.1046/j.1537-2995.1986.26286152919.x

Mitra, 1986, Elimination of infectious retroviruses during preparation of immunoglobulins, Transfusion, 26, 394, 10.1046/j.1537-2995.1986.26486262753.x

Henin, 1988, Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma, Vox Sang, 54, 78, 10.1111/j.1423-0410.1988.tb01621.x

Bos, 1998, Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process, Biologicals, 26, 267, 10.1006/biol.1998.0148

Hamamoto, 1987, Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation, Vox Sang, 53, 65, 10.1111/j.1423-0410.1987.tb04919.x

Uemura, 1989, Inactivation and elimination of viruses during the fractionation of an intravenous immunoglobulin preparation: liquid heat treatment and polyethylene glycol fractionation, Vox Sang, 56, 155, 10.1111/j.1423-0410.1989.tb02019.x

Omar, 1996, Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation, Transfusion, 36, 866, 10.1046/j.1537-2995.1996.361097017171.x

Biesert, 1996, Virus validation studies of immunoglobulin preparations, Clin Exp Rheumatol, 14, S47

Reid, 1988, Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products, Vox Sang, 55, 75, 10.1111/j.1423-0410.1988.tb05140.x

Boschetti, 2004, Different susceptibility of B19 virus and mice minute virus to low pH treatment, Transfusion, 44, 1079, 10.1111/j.1537-2995.2004.03420.x

Louie, 1994, Inactivation of hepatitis C virus in low pH intravenous immunoglobulin, Biologicals, 22, 13, 10.1006/biol.1994.1003

Poelsler, 2008, A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity, Vox Sang, 94, 184, 10.1111/j.1423-0410.2007.01016.x

WHO Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products http://www.WHO.int/bloodproducts WHO 2003

Hamalainen, 1992, Virus inactivation during intravenous immunoglobulin production, Vox Sang, 63, 6, 10.1111/j.1423-0410.1992.tb01211.x

Uemura, 1994, Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin, Vox Sang, 67, 246, 10.1111/j.1423-0410.1994.tb01246.x

Chandra, 1999, Virus reduction in the preparation of intravenous immune globulin: in vitro experiments, Transfusion, 39, 249, 10.1046/j.1537-2995.1999.39399219280.x

Chang, 2000, Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment, Prep Biochem Biotechnol, 30, 177, 10.1080/10826060008544957

Korneyeva, 2002, Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates, Biologicals, 30, 153, 10.1006/biol.2002.0334

Dichtelmuller, 2002, Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution, Biologicals, 30, 135, 10.1006/biol.2002.0332

Rojas, 1994, Caprylic acid fractionation of hyperimmune horse plasma: description of a simple procedure for antivenom production, Toxicon, 32, 351, 10.1016/0041-0101(94)90087-6

Burnouf, 2003, Nanofiltration of plasma-derived biopharmaceutical products, Haemophilia, 9, 24, 10.1046/j.1365-2516.2003.00701.x

Burnouf, 2005, Place of nanofiltration for assuring viral safety of biologicals, Curr Nanosci, 1, 189, 10.2174/157341305774642894

Troccoli, 1998, Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration, Biologicals, 26, 321, 10.1006/biol.1998.0164

Kreil, 2006, Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives, Transfusion, 46, 1143, 10.1111/j.1537-2995.2006.00864.x

CPMP, 1996, Note for Guidance on Virus Validation Studies: The Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses (Revised)

Llewelyn, 2004, Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion, Lancet, 363, 417, 10.1016/S0140-6736(04)15486-X

Hewitt, 2006, Creutzfeldt–Jakob disease and blood transfusion: results of the UK transfusion medicine epidemiological review study, Vox Sang, 91, 221, 10.1111/j.1423-0410.2006.00833.x

Eaton, 2009, Haemophilia patient had variant CJD agent in spleen, BMJ, 338, b705, 10.1136/bmj.b705

Foster, 2000, Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products, Vox Sang, 78, 86, 10.1046/j.1423-0410.2000.7820086.x

Flan, 2005, Evaluation de l’efficacité des procédés de purification des proteins plasmatiques àéliminer les agents transmissibles non conventionnels, Virologie, 9, S45

Reichl, 2002, Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin, Vox Sang, 83, 137, 10.1046/j.1423-0410.2002.00211.x

Trejo, 2003, Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process, Vox Sang, 84, 176, 10.1046/j.1423-0410.2003.00279.x

Radosevich, 2007, Biological and biochemical assays to ensure the quality and safety of plasma-derived products: Factor VIII concentrates, Curr Pharm Anal, 3, 83, 10.2174/157341207780598959

Kroez, 2003, Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation, Biologicals, 31, 277, 10.1016/j.biologicals.2003.09.001

Teschner, 2007, A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process, Vox Sang, 92, 42, 10.1111/j.1423-0410.2006.00846.x

Wagner, 1984, Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids, Anal Biochem, 136, 75, 10.1016/0003-2697(84)90308-7

Ramasamy, 1997, Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations, Biologicals, 25, 87, 10.1006/biol.1996.0063

Copelan, 1986, Hemolysis following intravenous immune globulin therapy, Transfusion, 26, 410, 10.1046/j.1537-2995.1986.26587020113.x

Turner, 1999, Anti-Rh D activity of commercial intravenous immunoglobulin preparations, Vox Sang, 76, 55, 10.1046/j.1423-0410.1999.7610055.x

Thorpe, 2003, Batches of intravenous immunoglobulin associated with adverse reactions in recipients contain atypically high anti-Rh D activity, Vox Sang, 85, 80, 10.1046/j.1423-0410.2003.00336.x

Thorpe, 2005, Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method, Biologicals, 33, 111, 10.1016/j.biologicals.2005.02.002

Thorpe, 2005, International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti-D in intravenous immunoglobulin products, Vox Sang, 88, 278, 10.1111/j.1423-0410.2005.00622.x

Romer, 1982, Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content, Vox Sang, 42, 62, 10.1159/000460851

Snape, 1979, The assay of prekallikrein activator in human blood products, Dev Biol Stand, 44, 115

Anonymous, 2007, Prekallicrein Activator 07/2006:20615

Kerry, 1985, Standardization of prekallikrein activator (PKA): the 1st International Standard for PKA, Br J Haematol, 60, 345, 10.1111/j.1365-2141.1985.tb07420.x

Kotitschke, 1993, Assessment of the Fc function in human immunoglobulins for intravenous administration. Multicenter study of the section ‘Blood plasma Constituents’ of the German Association for transfusion medicine and immunohematology (DGTI), Infusionsther Transfusionsmed, 20, 93

Vrdoljak, 2004, A microassay for measurement of Fc function of human immunoglobulin preparations by using tetanus toxoid as antigen, Biologicals, 32, 78, 10.1016/j.biologicals.2004.03.001

Reipert, 2006, Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solution, Vox Sang, 91, 256, 10.1111/j.1423-0410.2006.00828.x

Georgakopoulos, 2009, An improved method for the determination of Fc function of immunoglobulins, Vox Sang, 96, 133, 10.1111/j.1423-0410.2008.01125.x

Klein, 1985, The quantification of human IgG subclasses in reference preparations, Clin Chim Acta, 150, 119, 10.1016/0009-8981(85)90262-1

Dalakas, 1994, High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events, Neurology, 44, 223, 10.1212/WNL.44.2.223

Marie, 2006, Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature, Br J Dermatol, 155, 714, 10.1111/j.1365-2133.2006.07390.x

Wolberg, 2000, Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations, Am J Hematol, 65, 30, 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J

Burnouf-Radosevich, 1992, A therapeutic, highly purified factor XI concentrate from human plasma, Transfusion, 32, 861, 10.1046/j.1537-2995.1992.32993110761.x

Bleeker, 2000, Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase, Blood, 95, 1856, 10.1182/blood.V95.5.1856.005k03_1856_1861

Bleeker, 1987, An animal model for the detection of hypotensive side effects of immunoglobulin preparations, Vox Sang, 52, 281, 10.1111/j.1423-0410.1987.tb04894.x

Bayry, 2007, Shortage of human intravenous immunoglobulin: reasons and possible solutions, Nat Clin Pract Neurol, 3, 120, 10.1038/ncpneuro0429

Djoumerska, 2005, The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used, Scand J Immunol, 61, 357, 10.1111/j.1365-3083.2005.01568.x

Dimitrov, 2007, Transition towards antigen-binding promiscuity of a monospecific antibody, Mol Immunol, 44, 1854, 10.1016/j.molimm.2006.10.002

Lemieux, 2006, Autoantibody-induced formation of immune complexes in normal human serum, Curr Pharm Des, 12, 173, 10.2174/138161206775193055

St-Amour, Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins, Clin Immunol